Injectables, Evidence & Expectations
Part 2: PDRN (Polydeoxyribonucleotide)
“Regeneration” Needs Evidence
PDRN (polydeoxyribonucleotide) has rapidly entered aesthetic medicine under labels such as regenerative injectable, salmon DNA therapy, skin repair treatment, or biostimulator.
It is frequently promoted as capable of improving skin quality, reducing inflammation, stimulating collagen, accelerating healing, and reversing aging.
As with skin boosters, my goal of this review is not to dismiss the treatment entirely, but to separate biologic plausibility from demonstrated clinical outcomes. My patients already know that science-based aesthetics has always been at the core of how I approach this field.
The current problem is not that PDRN has no scientific basis. The problem is that many clinical claims go far beyond the strength of the evidence.
What PDRN Actually Is
PDRN consists of low-molecular-weight DNA fragments, most commonly derived from salmon or trout sperm.
It has been studied for years in wound healing and tissue repair, primarily because it appears to activate the adenosine A2A receptor pathway, which may influence:
Fibroblast activity
Angiogenesis (formation of blood vessels)
Anti-inflammatory signaling
Tissue repair mechanisms
This makes PDRN biologically interesting.
However, biologic activity alone does not automatically translate into meaningful or long-lasting aesthetic outcomes.
What Clinical Studies Actually Show
Most aesthetic studies on PDRN are:
Small samples
Non-randomized
Industry-sponsored
Based on subjective endpoints such as “skin glow”, elasticity, or patient satisfaction (not accurate endpoints, cannot be compared/repeated)
Some studies report modest improvements in:
Skin hydration
Texture and elasticity
Post-procedure healing
Particularly when combined with lasers, microneedling, radiofrequency, or other treatments. However:
High-quality randomized controlled trials remain limited
Objective histologic evidence is sparse
Long-term durability is poorly established
Importantly, most published studies evaluate PDRN as part of combination therapy, making it difficult to determine how much improvement comes from the injectable itself.
The “Collagen Stimulation” Problem
One of the most common marketing claims is that PDRN “stimulates collagen”. This is biologically plausible, and some laboratory studies suggest increased fibroblast activity (collagen secretion) under experimental conditions.
However, demonstrating fibroblast signaling in vitro is not the same as demonstrating clinically meaningful dermal remodeling in humans.
At present:
Robust histologic evidence (microscopic confirmation with tissue samples after injection) remains limited
Objective collagen quantification in aesthetic patients is lacking
No strong evidence demonstrates reversal of skin aging trajectories
The distinction matters as hydration, inflammation reduction, and temporary improvement in skin quality should not automatically be interpreted as regeneration.
Where PDRN May Have a Role
PDRN may be reasonable in selected situations:
Recovery after lasers or energy-based procedures
Mild improvement in skin hydration or texture
Adjunctive treatment in patients seeking subtle changes
Patients with irritated or inflamed skin barriers
The Under-Eye Area: One of the More Reasonable Indications
Interestingly, the periocular (under-eye) area is probably one of the few aesthetic indications where polynucleotides/PDRN have shown somewhat more consistent clinical improvement. A recent clinical study evaluating polynucleotides in the under-eye area demonstrated mild but measurable improvements in:
Fine rhytids (“crepey” wrinkles)
Skin texture and elasticity
Hydration
Importantly, the improvements were subtle (and I always make sure to tell my patients: subtle).
The treatment did not dramatically tighten skin or replace structural rejuvenation procedures such as blepharoplasty, fat repositioning, or energy-based resurfacing.
Why might the under-eye area respond better?
The lower eyelid has:
Extremely thin skin
Minimal dermal thickness
Early collagen loss
High sensitivity to hydration and inflammation changes
Because the skin is so thin in this region, even modest improvements in hydration or dermal quality may become clinically visible.
This is also probably why many patients notice:
Slight softening of fine lines
Improved “crepey” appearance
Better skin texture under makeup
rather than major volumetric or lifting effects.
The important distinction is that these studies mainly support modest improvement in skin quality, not true structural regeneration or reversal of aging.
What It Should Not Be Presented As
Current evidence does not support presenting PDRN as:
A replacement for structural rejuvenation
A true biostimulator comparable to established collagen-stimulating products
A treatment capable of reversing aging
A substitute for surgery or energy-based devices
Bottom Line
PDRN is biologically interesting and may improve certain superficial skin parameters or healing responses.
But at present, the evidence mainly supports modest, short-term improvements rather than proven regeneration or long-term structural remodeling.
As with many injectable trends in aesthetics, the marketing currently exceeds the data.
References
Bitto A, et al.
Polydeoxyribonucleotide (PDRN) restores blood flow in an experimental model of ischemic skin flaps.
J Vasc Surg. 2008.Kim JH, et al.
Polydeoxyribonucleotide improves skin repair and regeneration: experimental and clinical evidence.
Arch Craniofac Surg. 2020.Sini P, et al.
Adenosine receptor involvement in wound healing and tissue repair induced by polydeoxyribonucleotide.
J Cell Physiol. 2010.Cavallini M, et al.
The role of polydeoxyribonucleotide in aesthetic medicine and skin rejuvenation: a review.
J Cosmet Dermatol. 2022.Matarasso SL, et al.
Injectable skin quality treatments: mechanisms and limitations.
Aesthetic Surg J. 2019.
Park KY, et al.
Clinical effects of polynucleotide injections in the infraorbital area: improvement of fine wrinkles and skin quality.
J Cosmet Dermatol. 2023.